#BEGIN_DRUGCARD DB04608

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C20H12N2O3

# Chemical_IUPAC_Name:
14-hydroxy-7-phenyl-4,10-diazatetracyclo[7.7.0.0^{2,6}.0^{11,16}]hexadeca-1,6,8,11,13,15-hexaene-3,5-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2007-09-11 11:48:58 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE

# HET_ID:
824

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C20H12N2O3/c23-11-6-7-14-13(8-11)16-15(21-14)9-12(10-4-2-1-3-5-10)17-18(16)20(25)22-19(17)24/h1-9,21,23H,(H,22,24,25)

# InChI_Key:
InChIKey=IAUZTOZLTFSMIE-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4608

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
328.3209

# Molecular_Weight_Mono:
328.08479226

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
3.3

# Predicted_LogS:
-4.8

# Predicted_Water_Solubility:
4.68e-03 g/l

# Primary_Accession_No:
DB04608

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4369491

# PubChem_Substance_ID:
46505289

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC1=CC2=C(NC3=CC(=C4C(=O)NC(=O)C4=C23)C2=CC=CC=C2)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:30 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
WEE1

# Drug_Target_1_GenBank_ID_Gene:
U10564

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
WEE1

# Drug_Target_1_Gene_Sequence:
>1941 bp
ATGAGCTTCCTGAGCCGACAGCAGCCGCCGCCACCCCGCCGCGCCGGGGCGGCCTGCACC
TTGCGGCAGAAGCTGATCTTCTCGCCCTGCAGCGACTGTGAGGAGGAGGAAGAAGAGGAG
GAGGAGGAGGGCAGCGGCCACAGCACCGGGGAGGACTCGGCCTTTCAAGAGCCCGACTCG
CCGCTGCCGCCCGCGCGGAGCCCCACGGAGCCCGGGCCCGAGCGCCGCCGCTCGCCCGGG
CCGGCCCCCGGCAGCCCCGGCGAGCTGGAGGAGGACCTGTTGCTGCCCGGCGCCTGCCCG
GGCGCGGACGAGGCGGGCGGTGGGGCGGAGGGCGACTCGTGGGAGGAGGAGGGCTTCGGC
TCCTCGTCGCCGGTCAAGTCGCCGGCGGCCCCCTACTTCCTGGGTAGCTCTTTCTCGCCG
GTGCGCTGCGGCGGCCCAGGAGATGCGTCGCCGCGGGGTTGCGGGGCGCGCCGGGCGGGC
GAAGGCCGCCGCTCGCCGCGGCCGGACCACCCGGGCACCCCGCCACACAAGACCTTCCGC
AAGCTGCGACTCTTCGACACCCCGCACACGCCCAAGAGTTTGCTCTCCAAAGCTCGGGGA
ATTGATTCCAGCTCTGTTAAACTCCGGGGTAGTTCTCTCTTCATGGATACAGAAAAATCA
GGAAAAAGGGAATTTGATGTGCGACAGACTCCTCAAGTGAATATTAATCCTTTTACTCCG
GATTCTTTGTTGCTTCATTCCTCAGGACAGTGTCGTCGTAGAAAGAGAACGTATTGGAAT
GATTCCTGTGGTGAAGACATGGAAGCCAGTGATTATGAGCTTGAAGATGAAACAAGACCT
GCTAAGAGAATTACAATTACTGAAAGCAATATGAAGTCCCGGTATACAACAGAATTTCAT
GAGCTAGAGAAAATCGGCTCTGGAGAATTTGGTTCTGTATTTAAGTGTGTGAAGAGGCTG
GATGGATGCATTTATGCCATTAAGCGATCAAAAAAGCCATTGGCGGGCTCTGTTGATGAG
CAGAACGCTTTGAGAGAAGTATATGCTCATGCAGTGCTTGGACAGCATTCTCATGTAGTT
CGATATTTCTCTGCGTGGGCAGAAGATGATCATATGCTTATACAGAATGAATATTGTAAT
GGTGGAAGTTTAGCTGATGCTATAAGTGAAAACTACAGAATCATGAGTTACTTTAAAGAA
GCAGAGTTGAAGGATCTCCTTTTGCAAGTTGGCCGAGGCTTGAGGTATATTCATTCAATG
TCTTTGGTTCACATGGATATAAAACCTAGTAATATTTTCATATCTCGAACCTCAATCCCA
AATGCTGCCTCTGAAGAAGGAGACGAAGATGATTGGGCATCCAACAAAGTTATGTTTAAA
ATAGGTGATCTTGGGCATGTAACAAGGATCTCCAGTCCACAAGTTGAAGAGGGCGATAGT
CGTTTTCTTGCAAATGAAGTTTTACAGGAGAATTATACCCATCTACCAAAAGCAGATATT
TTTGCGCTTGCCCTCACAGTGGTATGTGCTGCTGGTGCTGAACCTCTTCCGAGAAATGGA
GATCAATGGCATGAAATCAGACAGGGTAGATTACCTCGGATACCACAAGTGCTTTCCCAA
GAATTTACAGAGTTGCTAAAAGTTATGATTCATCCAGATCCAGAGAGAAGACCTTCAGCA
ATGGCACTGGTAAAGCATTCAGTATTGCTGTCCGCTTCTAGAAAGAGTGCAGAACAATTA
CGAATAGAATTGAATGCCGAAAAGTTCAAAAATTCACTTTTACAAAAAGAACTCAAGAAA
GCACAGATGGCAAAAGCTGCAGCTGAGGAAAGAGCACTCTTCACTGACCGGATGGCCACT
AGGTCCACCACCCAGAGTAATAGAACATCTCGACTTATTGGAAAGAAAATGAACCGCTCT
GTCAGCCTTACTATATACTGA

# Drug_Target_1_General_Function:
Involved in protein kinase activity

# Drug_Target_1_General_References:
1840647	Igarashi M, Nagata A, Jinno S, Suto K, Okayama H: Wee1(+)-like gene in human cells. Nature. 1991 Sep 5;353(6339):80-3.
7743995	Watanabe N, Broome M, Hunter T: Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J. 1995 May 1;14(9):1878-91.
8428596	McGowan CH, Russell P: Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J. 1993 Jan;12(1):75-85.

# Drug_Target_1_HGNC_ID:
HGNC:12761

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5717

# Drug_Target_1_Locus:
11p15.3-p15.1

# Drug_Target_1_Molecular_Weight:
71598

# Drug_Target_1_Name:
Wee1-like protein kinase

# Drug_Target_1_Number_of_Residues:
646

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_1_Protein_Sequence:
>Wee1-like protein kinase
MSFLSRQQPPPPRRAGAACTLRQKLIFSPCSDCEEEEEEEEEEGSGHSTGEDSAFQEPDS
PLPPARSPTEPGPERRRSPGPAPGSPGELEEDLLLPGACPGADEAGGGAEGDSWEEEGFG
SSSPVKSPAAPYFLGSSFSPVRCGGPGDASPRGCGARRAGEGRRSPRPDHPGTPPHKTFR
KLRLFDTPHTPKSLLSKARGIDSSSVKLRGSSLFMDTEKSGKREFDVRQTPQVNINPFTP
DSLLLHSSGQCRRRKRTYWNDSCGEDMEASDYELEDETRPAKRITITESNMKSRYTTEFH
ELEKIGSGEFGSVFKCVKRLDGCIYAIKRSKKPLAGSVDEQNALREVYAHAVLGQHSHVV
RYFSAWAEDDHMLIQNEYCNGGSLADAISENYRIMSYFKEAELKDLLLQVGRGLRYIHSM
SLVHMDIKPSNIFISRTSIPNAASEEGDEDDWASNKVMFKIGDLGHVTRISSPQVEEGDS
RFLANEVLQENYTHLPKADIFALALTVVCAAGAEPLPRNGDQWHEIRQGRLPRIPQVLSQ
EFTELLKVMIHPDPERRPSAMALVKHSVLLSASRKSAEQLRIELNAEKFKNSLLQKELKK
AQMAKAAAEERALFTDRMATRSTTQSNRTSRLIGKKMNRSVSLTIY

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
May act as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDC2 before the onset of mitosis. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation. Specifically phosphorylates and inactivates cyclin B1-complexed CDC2 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDC2 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDC2 does not occur

# Drug_Target_1_SwissProt_ID:
P30291

# Drug_Target_1_SwissProt_Name:
WEE1_HUMAN

# Drug_Target_1_Synonyms:
EC 2.7.10.2
WEE1hu
Wee1A kinase

# Drug_Target_1_Theoretical_pI:
6.76

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB04608
